RxDoctor Payments Data

Marina Levin, MD

Hospitalist · San Diego, CANPI 1023209798

Payments from drug & device makers

$659in general payments, 2019–2025

Across 33 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$143
  • Lilly USA, LLC$121
  • GSK$104
  • Novo Nordisk$97
  • Merck$49
  • Pfizer$31
  • plus $113 from 6 others

What the payments were for

  • Food & beverage$659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen8$143
Lilly USA, LLC5$121
GSK5$104
Novo Nordisk5$97
Merck2$49
Pfizer2$31
Hologic Sales And Service, LLC1$25
Abbott1$23
Boehringer Ingelheim1$20
AstraZeneca1$18
Exact Sciences1$16
Biowound Solutions, Inc.1$11

How this compares

$659 in reported general payments places this provider in the 85th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$59,902
Medicare patients
145
Services billed
643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide22$43,326
OzempicSemaglutide23$40,040
EliquisApixaban35$39,644
JardianceEmpagliflozin24$33,025
JanuviaSitagliptin Phosphate11$7,967
Semglee (Yfgn) PenInsulin Glargine-Yfgn16$3,287
Duloxetine Hcl37$2,784
Celecoxib28$2,060
Rosuvastatin Calcium121$1,973
Tamsulosin Hcl78$1,858
Atorvastatin Calcium200$1,746
Levothyroxine Sodium128$1,475
Gabapentin86$1,455
Estradiol13$1,408
Pantoprazole Sodium54$1,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$121$43,32622 claims
Novo NordiskOzempic$97$40,04023 claims
PfizerEliquis$31$39,64435 claims
Boehringer IngelheimJardiance$20$33,02524 claims
MerckJanuvia$49$7,96711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,469 hospitalist providers in California.

Other hospitalist in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →